“…SB-220453 (now known as tonabersat) is a benzoylamino-benzopyran compound that has shown the ability to inhibit CSD in animal models of migraine [2]. Great interest has developed with regard to the possibility that pharmacologic CSD inhibition may prevent migraine headache attacks, although in a human model of migraine, tonabersat failed as a preemptive antimigraine agent in a double-blind study [2]. For prophylaxis, however, commonly prescribed migraine preventatives such as topiramate, valproate, propranolol, and amitriptyline all were recently found to inhibit CSD in a dose-dependent fashion when administered chronically and on a daily basis in rats, suggesting that CSD can provide a common therapeutic target for migraine prophylactic drugs [3].…”